17
Participants
Start Date
December 15, 2021
Primary Completion Date
April 12, 2023
Study Completion Date
April 12, 2023
Velusetrag 15 mg once daily for 4 weeks.
Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
Placebo once daily for 4 weeks.
Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
Aou Arcispedale Sant'Anna Di Cona, Cona
Policlinico S.Orsola-Malpighi, Bologna
UZ Leuven Gasthuisberg Campus, Leuven
Hospital General Vall Hebron, Barcelona
Lead Sponsor
Alfasigma S.p.A.
INDUSTRY